Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

Fig. 4

Antibody humanization and characterization of ADU-1805. a Binding of ADU-1805 to erythrocyte-depleted whole blood. (Mean; representative of n = 6 donors is shown). b ADU-1805 promotes macrophage-mediated tumor cell uptake, triggered by RTX. (Mean ± SD; representative of n = 7 donors is shown). Data were analyzed by unpaired two-sided Student’s t-test. * indicate statistical differences compared to the RTX control group: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant. c The principle of tumor cell trogocytosis (trogo = nibble), a process by which neutrophils take small bites from target cells. Flow cytometry analysis demonstrates that ADU-1805 enhances anti-tumor antibody-induced trogocytosis in a dose-dependent manner. d Quantification of tumor cell trogocytosis by human neutrophils. (Mean ± SD; representative of n = 6 is shown). Data were analyzed by unpaired two-sided Student’s t-test. * indicate statistical differences compared to the respective isotype control group: ***p < 0.001, ****p < 0.0001

Back to article page